COVID Vaccine Response Varies by Blood Cancer Type, Treatment

Patients with AML and high-risk MDS had stronger immune responses after two vaccine doses than patients with ALL. This study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/972428?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost